Green oat cognitaven® attenuates mild cognitive impairment by activating the CREB/BDNF/Nrf2/HO-1 pathway and modulating NF-κB/MAPK signaling.

Balakrishnan R, Kim YS, Kang SI, Choi DK

Open source

DOI
10.1016/j.biopha.2025.118295
Published
2025 Aug
Container
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.biopha.2025.118295,
  title = {Green oat cognitaven® attenuates mild cognitive impairment by activating the CREB/BDNF/Nrf2/HO-1 pathway and modulating NF-κB/MAPK signaling.},
  author = {Balakrishnan R and Kim YS and Kang SI and Choi DK},
  year = {2025},
  journal = {Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  doi = {10.1016/j.biopha.2025.118295},
  url = {https://doi.org/10.1016/j.biopha.2025.118295}
}

RIS

TY  - JOUR
TI  - Green oat cognitaven® attenuates mild cognitive impairment by activating the CREB/BDNF/Nrf2/HO-1 pathway and modulating NF-κB/MAPK signaling.
AU  - Balakrishnan R
AU  - Kim YS
AU  - Kang SI
AU  - Choi DK
PY  - 2025
JO  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
DO  - 10.1016/j.biopha.2025.118295
UR  - https://doi.org/10.1016/j.biopha.2025.118295
ER  - 

APA

R, B., YS, K., SI, K., & DK, C. (2025). Green oat cognitaven® attenuates mild cognitive impairment by activating the CREB/BDNF/Nrf2/HO-1 pathway and modulating NF-κB/MAPK signaling.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2025.118295

Source records